Compare Viatris Inc (VTRS) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Western Union Co — how do they compare? Viatris Inc trades at $16.14 (market cap $18.69B), while Western Union Co trades at $7.11 (market cap $2.20B). The key difference: Viatris Inc is far larger — about 8.5× Western Union Co's market cap, and Western Union Co pays the higher dividend (13.33%). Which is the better fit depends on your goals.
| VTRS | WU | |
|---|---|---|
Market Cap | $18.69B | $2.20B |
Sector | Health | Technology |
52-Week High | $17.86 | $10.28 |
52-Week Low | $9.49 | $6.36 |
Enterprise Value | $30.80B | $2.10B |
Dividend Yield | 2.95% | 13.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Western Union (WU) trades at $6.985, down 0.64% on the day, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. The company maintains a dividend of $0.24 per share and shows strong profitability with a 9.79% net income margin and 43.97% ROE, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. Analyst consensus is mixed with a $7.14 price target, but news highlights challenges like retail money transfer weakness and strategic shifts.
The outlook is cautious due to declining revenue, earnings volatility, and bearish sentiment, though low valuation ratios (P/E of 5.69) may appeal to value investors. Risks include competitive pressures and execution hurdles in digital transitions, requiring close monitoring of upcoming Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
